Safety Concern between Autologous Fat Graft, Mesenchymal Stem Cell and Osteosarcoma Recurrence

Background Osteosarcoma is the most common malignant primary bone tumour in young adult treated by neo adjuvant chemotherapy, surgical tumor removal and adjuvant multidrug chemotherapy. For correction of soft tissue defect consecutive to surgery and/or tumor treatment, autologous fat graft has been proposed in plastic and reconstructive surgery. Principal Findings We report here a case of a late local recurrence of osteosarcoma which occurred 13 years after the initial pathology and 18 months after a lipofilling procedure. Because such recurrence was highly unexpected, we investigated the possible relationship of tumor growth with fat injections and with mesenchymal stem/stromal cell like cells which are largely found in fatty tissue. Results obtained in osteosarcoma pre-clinical models show that fat grafts or progenitor cells promoted tumor growth. Significance These observations and results raise the question of whether autologous fat grafting is a safe reconstructive procedure in a known post neoplasic context.

[1]  M. Salgarello,et al.  Autologous Fat Graft in Radiated Tissue Prior to Alloplastic Reconstruction of the Breast: Report of Two Cases , 2010, Aesthetic Plastic Surgery.

[2]  Gang Li,et al.  Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis. , 2009, Cancer letters.

[3]  B. Lévy,et al.  Preconditioning by Mitochondrial Reactive Oxygen Species Improves the Proangiogenic Potential of Adipose-Derived Cells–Based Therapy , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[4]  D. Rose,et al.  Angiogenesis, adipokines and breast cancer. , 2009, Cytokine & growth factor reviews.

[5]  Rong Li,et al.  Interleukin 6 Secreted from Adipose Stromal Cells Promotes Migration and Invasion of Breast Cancer Cells , 2009, Oncogene.

[6]  M. Saint-Cyr,et al.  Autologous fat transfer: controversies and current indications for breast surgery. , 2009, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[7]  D. Banerjee,et al.  Mesenchymal stem cells: flip side of the coin. , 2009, Cancer research.

[8]  M. Padrines,et al.  Proteases and bone remodelling. , 2009, Cytokine & growth factor reviews.

[9]  E. Miot-Noirault,et al.  Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma. , 2009, Cancer research.

[10]  C. W. Chan,et al.  Autologous fat transfer--a review of the literature with a focus on breast cancer surgery. , 2008, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[11]  B. Pitard,et al.  Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma , 2010 .

[12]  S. Spear Fat for breast: where are we? , 2008, Plastic and reconstructive surgery.

[13]  E. Motrescu,et al.  Cancer cells, adipocytes and matrix metalloproteinase 11: a vicious tumor progression cycle , 2008, Biological chemistry.

[14]  C. Jorgensen,et al.  Concise Review: Adult Multipotent Stromal Cells and Cancer: Risk or Benefit? , 2008, Stem cells.

[15]  J. Chirgwin,et al.  Molecular biology of bone metastasis. , 2008, Molecular cancer therapeutics.

[16]  E. Delay,et al.  [Lipomodelling for correction of breast conservative treatment sequelae. Medicolegal aspects. Expert opinion on five problematic clinical cases]. , 2008, Annales de chirurgie plastique et esthetique.

[17]  E. Delay,et al.  Efficacité du lipomodelage pour la correction des séquelles du traitement conservateur du cancer du sein , 2008 .

[18]  E. Delay,et al.  Lipomodelage et correction des séquelles du traitement conservateur du cancer du sein: Aspects médicolégaux. Le point de vue de l’expert à partir de cinq cas cliniques délicats , 2008 .

[19]  A. Varan,et al.  LATE RECURRENCE IN PRIMARY REGION OF PAROSTEAL OSTEOSARCOMA: A CASE REPORT , 2008, Pediatric hematology and oncology.

[20]  Michael Baum,et al.  Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures , 2007, Nature Clinical Practice Oncology.

[21]  K. Harii,et al.  Cell-Assisted Lipotransfer for Cosmetic Breast Augmentation: Supportive Use of Adipose-Derived Stem/Stromal Cells , 2007, Aesthetic Plastic Surgery.

[22]  B. Pitard,et al.  Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. , 2007, Cancer research.

[23]  C. Balleyguier,et al.  Autologous fat transfer in reconstructive breast surgery: indications, technique and results. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[24]  D. Jeon,et al.  Time Dependency of Prognostic Factors in Patients with Stage II Osteosarcomas , 2007, Clinical orthopaedics and related research.

[25]  N. Gallay,et al.  The In Vitro Migration Capacity of Human Bone Marrow Mesenchymal Stem Cells: Comparison of Chemokine and Growth Factor Chemotactic Activities , 2007, Stem cells.

[26]  E. Schwarz,et al.  Clinical development of anti-RANKL therapy , 2007, Arthritis research & therapy.

[27]  S. Coleman,et al.  Fat Grafting to the Breast Revisited: Safety and Efficacy , 2007, Plastic and reconstructive surgery.

[28]  F. Djouad,et al.  Earlier Onset of Syngeneic Tumors in the Presence of Mesenchymal Stem Cells , 2006, Transplantation.

[29]  H. Xie,et al.  Adiponectin Stimulates RANKL and Inhibits OPG Expression in Human Osteoblasts Through the MAPK Signaling Pathway , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  S. Ferrari,et al.  Late Relapse in Osteosarcoma , 2006, Journal of pediatric hematology/oncology.

[31]  M. Raffeld,et al.  Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma , 2006, The Journal of experimental medicine.

[32]  S. M. Sims,et al.  Regulation of cancer cell migration and bone metastasis by RANKL , 2006, Nature.

[33]  David Zurakowski,et al.  A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. , 2006, Journal of the National Cancer Institute.

[34]  M. Heymann,et al.  Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma‐bearing mice , 2005, Cancer.

[35]  Edward W Scott,et al.  Stem-like cells in bone sarcomas: implications for tumorigenesis. , 2005, Neoplasia.

[36]  H. Tsuda,et al.  Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model , 2004, Gene Therapy.

[37]  Keith L. March,et al.  Secretion of Angiogenic and Antiapoptotic Factors by Human Adipose Stromal Cells , 2004, Circulation.

[38]  J. Gimble,et al.  Bone and fat , 2004, Endocrine.

[39]  W. Dougall,et al.  Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. , 2003, Cancer research.

[40]  J. Dennis,et al.  Origin and Differentiation of Human and Murine Stroma , 2002, Stem cells.

[41]  I. Holen,et al.  Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. , 2001, Blood.

[42]  J. Michaeli,et al.  Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[43]  P. Kostenuik,et al.  Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. , 2001, Cancer research.

[44]  S. Ferrari,et al.  Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Furukawa,et al.  Microvascular Angiogenesis and Apoptosis in the Survival of Free Fat Grafts , 2000, The Laryngoscope.

[46]  T. Koshino,et al.  Predictive value of serum immunosuppressive acidic protein for lung metastasis after amputation of murine osteosarcoma of the lower limb. , 2000, Cancer letters.

[47]  M. Padrines,et al.  Cysteine protease production by human osteosarcoma cells (MG63, SAOS2) and its modulation by soluble factors. , 2000, Cytokine.

[48]  F. Higashino,et al.  Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  S. Ferrari,et al.  Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  S. Coleman Facial recontouring with lipostructure. , 1997, Clinics in plastic surgery.

[51]  C. Emerson,et al.  10T1/2 cells: an in vitro model for molecular genetic analysis of mesodermal determination and differentiation. , 1989, Environmental health perspectives.

[52]  T. Orfeo,et al.  One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. , 1977, Journal of the National Cancer Institute.

[53]  S. Pallante,et al.  Complexes of organic acids with calcium phosphate: the von Kossa stain as a clue to the composition of bone mineral. , 1971, The Johns Hopkins medical journal.

[54]  M. Delbaere,et al.  [Efficacy of lipomodelling for the management of sequelae of breast cancer conservative treatment]. , 2008, Annales de chirurgie plastique et esthetique.

[55]  D. Argyle,et al.  Isolation and characterisation of cancer stem cells from canine osteosarcoma. , 2008, Veterinary journal.

[56]  E. Delay,et al.  [Radiological evaluation after lipomodelling for correction of breast conservative treatment sequelae]. , 2008, Annales de chirurgie plastique et esthetique.

[57]  D. Heath,et al.  An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. , 2007, Cancer research.

[58]  F. Djouad,et al.  Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. , 2003, Blood.

[59]  W. Winkelmann,et al.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  G Rosen,et al.  Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  J. Lundy,et al.  A model of tumor cell dormancy: Effects of anesthesia and surgery , 1981, Journal of surgical oncology.